FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902016504> ?p ?o ?g. }

• W2902016504 endingPage "886" @default.
• W2902016504 startingPage "878" @default.
• W2902016504 abstract "To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM).Trial RTOG 04-20, a single-arm, multi-institutional phase 2 trial, was designed to determine the efficacy and toxicity of concomitant TMZ and radiation therapy (RT) followed by adjuvant TMZ combined with CPT-11 given for 12 cycles compared with historical controls of adjuvant TMZ alone given for 6 cycles.A total of 170 patients were enrolled, 152 of whom were eligible. Adjuvant CPT-11 combined with TMZ was more toxic than expected. A higher rate of hematologic and gastrointestinal toxicities was more frequently noted with the combination regimen compared with adjuvant TMZ alone. Grade 3/4 hematologic toxicity was 38% compared with 14% reported in the Stupp trial. After an early interim analysis, the adjuvant CPT-11 dose was reduced to 100 mg/m2 on days 1 and 5 for the first cycle. CPT-11 dose escalation proceeded over the first 3 cycles if tolerated. Median overall survival for all eligible patients was 16.9 months compared with 13.7 months of the historical control (P = .03). Post hoc subgroup analysis suggested an improvement in overall survival for patients with Radiation Therapy Oncology Group recursive partitioning analysis class 3, although improvement was limited to 22 patients (14% of eligible patients).Although irinotecan and TMZ for 12 cycles given after chemoradiation for patients with newly diagnosed glioblastoma significantly improved median survival compared with historical control data at the time the study was conducted, the historical control median survival time of 13.7 months does not represent the current benchmark for this patient population. Treatment intensification does prolong overall survival compared with the current standard." @default.
• W2902016504 created "2018-12-11" @default.
• W2902016504 creator A5003515749 @default.
• W2902016504 creator A5003825991 @default.
• W2902016504 creator A5014264452 @default.
• W2902016504 creator A5026088869 @default.
• W2902016504 creator A5036071138 @default.
• W2902016504 creator A5038585908 @default.
• W2902016504 creator A5039026260 @default.
• W2902016504 creator A5040919350 @default.
• W2902016504 creator A5066404810 @default.
• W2902016504 creator A5084926889 @default.
• W2902016504 creator A5086655595 @default.
• W2902016504 date "2019-03-01" @default.
• W2902016504 modified "2023-10-16" @default.
• W2902016504 title "Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420" @default.
• W2902016504 cites W1536538430 @default.
• W2902016504 cites W1975284341 @default.
• W2902016504 cites W1978041336 @default.
• W2902016504 cites W1980170616 @default.
• W2902016504 cites W1994497191 @default.
• W2902016504 cites W2047756740 @default.
• W2902016504 cites W2055159778 @default.
• W2902016504 cites W2059944898 @default.
• W2902016504 cites W2096287682 @default.
• W2902016504 cites W2099808007 @default.
• W2902016504 cites W2101183874 @default.
• W2902016504 cites W2105100844 @default.
• W2902016504 cites W2108285412 @default.
• W2902016504 cites W2112014411 @default.
• W2902016504 cites W2116575184 @default.
• W2902016504 cites W2118311655 @default.
• W2902016504 cites W2124736921 @default.
• W2902016504 cites W2135947790 @default.
• W2902016504 cites W2142013309 @default.
• W2902016504 cites W2156330848 @default.
• W2902016504 cites W2161216730 @default.
• W2902016504 cites W2161495439 @default.
• W2902016504 cites W2169869816 @default.
• W2902016504 cites W4230848571 @default.
• W2902016504 cites W4255214479 @default.
• W2902016504 doi "https://doi.org/10.1016/j.ijrobp.2018.11.008" @default.
• W2902016504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7034757" @default.
• W2902016504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30496882" @default.
• W2902016504 hasPublicationYear "2019" @default.
• W2902016504 type Work @default.
• W2902016504 sameAs 2902016504 @default.
• W2902016504 citedByCount "10" @default.
• W2902016504 countsByYear W29020165042020 @default.
• W2902016504 countsByYear W29020165042021 @default.
• W2902016504 countsByYear W29020165042022 @default.
• W2902016504 countsByYear W29020165042023 @default.
• W2902016504 crossrefType "journal-article" @default.
• W2902016504 hasAuthorship W2902016504A5003515749 @default.
• W2902016504 hasAuthorship W2902016504A5003825991 @default.
• W2902016504 hasAuthorship W2902016504A5014264452 @default.
• W2902016504 hasAuthorship W2902016504A5026088869 @default.
• W2902016504 hasAuthorship W2902016504A5036071138 @default.
• W2902016504 hasAuthorship W2902016504A5038585908 @default.
• W2902016504 hasAuthorship W2902016504A5039026260 @default.
• W2902016504 hasAuthorship W2902016504A5040919350 @default.
• W2902016504 hasAuthorship W2902016504A5066404810 @default.
• W2902016504 hasAuthorship W2902016504A5084926889 @default.
• W2902016504 hasAuthorship W2902016504A5086655595 @default.
• W2902016504 hasBestOaLocation W29020165042 @default.
• W2902016504 hasConcept C121608353 @default.
• W2902016504 hasConcept C126322002 @default.
• W2902016504 hasConcept C143998085 @default.
• W2902016504 hasConcept C2776694085 @default.
• W2902016504 hasConcept C2777389519 @default.
• W2902016504 hasConcept C2777863537 @default.
• W2902016504 hasConcept C2777982462 @default.
• W2902016504 hasConcept C2779384505 @default.
• W2902016504 hasConcept C2780259306 @default.
• W2902016504 hasConcept C2781413609 @default.
• W2902016504 hasConcept C31760486 @default.
• W2902016504 hasConcept C509974204 @default.
• W2902016504 hasConcept C526805850 @default.
• W2902016504 hasConcept C535046627 @default.
• W2902016504 hasConcept C61943457 @default.
• W2902016504 hasConcept C71924100 @default.
• W2902016504 hasConceptScore W2902016504C121608353 @default.
• W2902016504 hasConceptScore W2902016504C126322002 @default.
• W2902016504 hasConceptScore W2902016504C143998085 @default.
• W2902016504 hasConceptScore W2902016504C2776694085 @default.
• W2902016504 hasConceptScore W2902016504C2777389519 @default.
• W2902016504 hasConceptScore W2902016504C2777863537 @default.
• W2902016504 hasConceptScore W2902016504C2777982462 @default.
• W2902016504 hasConceptScore W2902016504C2779384505 @default.
• W2902016504 hasConceptScore W2902016504C2780259306 @default.
• W2902016504 hasConceptScore W2902016504C2781413609 @default.
• W2902016504 hasConceptScore W2902016504C31760486 @default.
• W2902016504 hasConceptScore W2902016504C509974204 @default.
• W2902016504 hasConceptScore W2902016504C526805850 @default.
• W2902016504 hasConceptScore W2902016504C535046627 @default.
• W2902016504 hasConceptScore W2902016504C61943457 @default.
• W2902016504 hasConceptScore W2902016504C71924100 @default.
• W2902016504 hasFunder F4320307765 @default.

• next